PT2744826T - Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina - Google Patents

Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina

Info

Publication number
PT2744826T
PT2744826T PT127458834T PT12745883T PT2744826T PT 2744826 T PT2744826 T PT 2744826T PT 127458834 T PT127458834 T PT 127458834T PT 12745883 T PT12745883 T PT 12745883T PT 2744826 T PT2744826 T PT 2744826T
Authority
PT
Portugal
Prior art keywords
antibody
combination therapy
purine analog
purine
analog
Prior art date
Application number
PT127458834T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of PT2744826T publication Critical patent/PT2744826T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT127458834T 2011-08-16 2012-08-14 Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina PT2744826T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11177660 2011-08-16

Publications (1)

Publication Number Publication Date
PT2744826T true PT2744826T (pt) 2022-05-19

Family

ID=47714800

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127458834T PT2744826T (pt) 2011-08-16 2012-08-14 Terapia de combinação com um anticorpo anti-cd19 e um análogo de purina

Country Status (25)

Country Link
US (3) US20140227277A1 (https=)
EP (2) EP4083071A3 (https=)
JP (1) JP6114273B2 (https=)
KR (3) KR20200060779A (https=)
CN (1) CN103703027B (https=)
AU (1) AU2012296905B2 (https=)
BR (1) BR112013033916B1 (https=)
CA (1) CA2841738C (https=)
CY (1) CY1125148T1 (https=)
DK (1) DK2744826T3 (https=)
ES (1) ES2909720T3 (https=)
HR (1) HRP20220224T1 (https=)
HU (1) HUE058855T2 (https=)
IL (1) IL230295B (https=)
LT (1) LT2744826T (https=)
MX (1) MX353589B (https=)
PL (1) PL2744826T3 (https=)
PT (1) PT2744826T (https=)
RS (1) RS63121B1 (https=)
RU (1) RU2664462C9 (https=)
SG (1) SG10201606788VA (https=)
SI (1) SI2744826T1 (https=)
SM (1) SMT202200160T1 (https=)
WO (1) WO2013024095A1 (https=)
ZA (1) ZA201401835B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
ES2523901B1 (es) * 2013-05-31 2015-12-02 Universidad Autónoma de Madrid Uso de la deguelina como terapia suplementaria de la leucemia linfoide crónica
JP2017519757A (ja) * 2014-06-16 2017-07-20 ゼンコー・インコーポレイテッドXencor、 Inc. 慢性リンパ球性白血病(cll)の処置
IL249533A0 (en) * 2014-06-16 2017-02-28 Xencor Inc Treatment of chronic lymphocytic leukemia
LT3302550T (lt) 2015-05-26 2019-11-11 Morphosys Ag Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
SMT202100541T1 (it) * 2015-08-21 2021-11-12 Morphosys Ag Combinazioni e loro usi
RS62155B1 (sr) * 2016-05-30 2021-08-31 Morphosys Ag Postupci predviđanja terapijske koristi anti-cd19 terapije kod pacijenata
IL301786B2 (en) * 2016-10-28 2025-09-01 Morphosys Ag Combination of anti-CD19 antibody with BCL-2 inhibitor and their uses
HRP20231229T1 (hr) * 2017-05-31 2024-02-02 Morphosys Ag Paradigma liječenja za protutijelo anti-cd19 i venetoklaks kombinacijsko liječenje
WO2019011918A1 (en) 2017-07-10 2019-01-17 International - Drug - Development - Biotech TREATMENT OF LYMPHOCYTE B MALIGNANCIES USING AFUCOSYLATED PRO-APOPTOTIC ANTI-CD19 ANTIBODIES IN COMBINATION WITH ANTI-CD20 ANTIBODIES OR CHEMOTHERAPEUTIC AGENTS
KR20200030337A (ko) 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
WO2020150513A1 (en) * 2019-01-17 2020-07-23 Fred Hutchinson Cancer Research Center Methods to enhance the selectivity and effectiveness of cancer treatments
TW202334231A (zh) * 2021-12-22 2023-09-01 德商莫菲西斯公司 抗cd19抗體療法的治療範例
CN121729431A (zh) 2023-07-13 2026-03-24 克里斯蒂安-阿尔伯特基尔大学 人源化抗cd7抗体

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US106A (en) 1915-08-24 Specipication
US11852A (en) 1854-10-31 Abraham bassford
US4708871A (en) 1983-03-08 1987-11-24 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
CA2340091C (en) * 1998-08-11 2013-02-05 Idec Pharmaceuticals Corporation Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
CA2375912C (en) * 1999-06-09 2014-03-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target b-cells
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
CA2467633C (en) 2001-12-03 2012-03-27 Abgenix, Inc. Antibody categorization based on binding characteristics
US20080260731A1 (en) * 2002-03-01 2008-10-23 Bernett Matthew J Optimized antibodies that target cd19
US7902338B2 (en) * 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
EP2216342B1 (en) 2003-07-31 2015-04-22 Immunomedics, Inc. Anti-CD19 antibodies
US8444973B2 (en) 2005-02-15 2013-05-21 Duke University Anti-CD19 antibodies and uses in B cell disorders
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
WO2007064911A1 (en) * 2005-12-02 2007-06-07 Biogen Idec Inc. Anti-mouse cd20 antibodies and uses thereof
AU2006332155B2 (en) 2005-12-30 2013-01-10 Cancer Research Technology Limited Anti-CD19 antibodies with reduced immunogenicity
PL2383297T3 (pl) * 2006-08-14 2013-06-28 Xencor Inc Zoptymalizowane przeciwciała ukierunkowane na CD19
KR101456728B1 (ko) 2006-09-08 2014-10-31 메디뮨 엘엘씨 인간화 항-cd19 항체, 및 이것의 종양학, 이식 및 자가면역 질환의 치료에서의 용도
CA2693053C (en) * 2007-05-30 2021-01-05 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
RU2476441C2 (ru) 2007-10-19 2013-02-27 Сиэтл Дженетикс, Инк. Cd19-связывающие средства и их применение
EP2398829A2 (en) 2009-02-23 2011-12-28 Glenmark Pharmaceuticals S.A. Humanized antibodies that bind to cd19 and their uses
EP2445530B1 (en) 2009-06-24 2016-09-07 The Feinstein Institute for Medical Research Method for treating chronic lymphocytic leukemia
TWI409079B (zh) * 2009-08-14 2013-09-21 Roche Glycart Ag 非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
KR20120054069A (ko) * 2009-08-14 2012-05-29 로슈 글리카트 아게 플루다라빈 및/또는 미토잔트론과 어푸코실화된 cd20 항체의 복합 요법
CA2779424A1 (en) * 2009-11-06 2011-05-12 Infinity Pharmaceuticals, Inc. Oral formulations of a hedgehog pathway inhibitor

Also Published As

Publication number Publication date
KR20140071368A (ko) 2014-06-11
EP2744826B1 (en) 2022-02-09
DK2744826T3 (da) 2022-03-28
KR102117202B1 (ko) 2020-06-01
ZA201401835B (en) 2015-06-24
KR20200060779A (ko) 2020-06-01
CA2841738A1 (en) 2013-02-21
WO2013024095A1 (en) 2013-02-21
JP2014525925A (ja) 2014-10-02
RS63121B1 (sr) 2022-05-31
SMT202200160T1 (it) 2022-05-12
PL2744826T3 (pl) 2022-05-30
CA2841738C (en) 2022-12-06
RU2014103490A (ru) 2015-09-27
HRP20220224T1 (hr) 2022-04-29
NZ617771A (en) 2016-01-29
AU2012296905B2 (en) 2017-01-05
ES2909720T3 (es) 2022-05-10
EP4083071A2 (en) 2022-11-02
SI2744826T1 (sl) 2022-05-31
JP6114273B2 (ja) 2017-04-12
EP4083071A3 (en) 2023-02-22
CN103703027B (zh) 2018-01-12
RU2664462C9 (ru) 2018-09-28
MX2013014935A (es) 2014-07-09
SG10201606788VA (en) 2016-09-29
BR112013033916B1 (pt) 2022-11-16
RU2664462C2 (ru) 2018-08-17
US20140227277A1 (en) 2014-08-14
CN103703027A (zh) 2014-04-02
HUE058855T2 (hu) 2022-09-28
KR20190094478A (ko) 2019-08-13
BR112013033916A2 (pt) 2017-11-28
EP2744826A1 (en) 2014-06-25
LT2744826T (lt) 2022-04-25
CY1125148T1 (el) 2024-12-13
IL230295B (en) 2018-03-29
US20240424012A1 (en) 2024-12-26
US20200352975A1 (en) 2020-11-12
MX353589B (es) 2018-01-19

Similar Documents

Publication Publication Date Title
ZA201401835B (en) Combination therapy with an anti-cd19 antibody and a purine analog
IL281250A (en) Anti-PHF-tau antibodies and uses thereof
DK2729170T3 (en) Antibody variants and uses thereof
IL232407A0 (en) Tests and methods for choosing treatment methods for those with depression
EP2756094A4 (en) ANTI-B7-H4 ANTIBODIES AND USES THEREOF
EP2712427A4 (en) SEISMIC DETECTION WITH TWO-COMPONENT SOURCE AND DEGHOSTING OF SOURCE
GB201110783D0 (en) Methods and uses
IL230293B (en) Combined treatment with anti-19cd antibody and nitrogen mustard
GB201116774D0 (en) Uses and methods
IL224953A (en) Theobromine-containing preparations and their use in combination with a debilitating drug
EP2716359A4 (en) COMPLEX AND USES THEREOF
EP2721788A4 (en) METHOD AND ARRANGEMENT FOR SENDING QUESTIONS
GB201108490D0 (en) Methods and uses
AU340918S (en) A vehicle and a toy vehicle
ZA201401628B (en) Antiballistic article with resin
GB201114341D0 (en) Reagent and use
GB201119443D0 (en) GoWinging Concept and patent
IL215565A0 (en) Bed with accessible and usable space
GB201107656D0 (en) Short back and sides